Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway

The latest announcement is out from Rocket Pharmaceuticals ( (RCKT) ).

On April 26, 2026, Rocket Pharmaceuticals entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher that it was awarded after the U.S. Food and Drug Administration granted accelerated approval to its gene therapy KRESLADI for severe leukocyte adhesion deficiency-I in pediatric patients. The buyer will pay $180 million in cash for the voucher, with closing subject to customary conditions including clearance under U.S. antitrust review rules.

Rocket said on April 28, 2026 that monetizing the voucher provides $180 million of non-dilutive capital, extending its cash runway into the second quarter of 2028 and reinforcing its strategy of prioritizing cardiovascular gene therapy programs. The proceeds are earmarked to advance clinical-stage candidates for Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy, strengthening the company’s funding profile as competition intensifies in genetic therapies for rare cardiac disorders.

The most recent analyst rating on (RCKT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Rocket Pharmaceuticals stock, see the RCKT Stock Forecast page.

Spark’s Take on RCKT Stock

According to Spark, TipRanks’ AI Analyst, RCKT is a Neutral.

The score is held down primarily by weak financial performance (no revenue, persistent losses, and ongoing cash burn). Technicals are only mildly supportive, while valuation is constrained by negative earnings and no dividend. Offsetting these, the FDA accelerated approval and Priority Review Voucher are meaningful positives that improve the outlook and financial flexibility.

To see Spark’s full report on RCKT stock, click here.

More about Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. is a fully integrated, commercial-stage biotechnology company focused on gene therapies for rare and devastating cardiovascular diseases, with additional programs in hematology and immunology. Its cardiovascular pipeline includes three clinical-stage programs targeting hypertrophic, arrhythmogenic and dilated inherited cardiomyopathies, addressing more than 100,000 patients in the U.S. and EU.

The company leverages proprietary AAV manufacturing capabilities and multi-year efficacy and safety data in cardiac gene therapy, and it has experience treating cardiac patients in late-stage AAV programs. Rocket is listed on Nasdaq under the ticker RCKT and operates out of Cranbury, New Jersey.

Average Trading Volume: 3,289,814

Technical Sentiment Signal: Sell

Current Market Cap: $384.1M

See more data about RCKT stock on TipRanks’ Stock Analysis page.